Αποτελέσματα Αναζήτησης
2 Απρ 2012 · The Panel recommends full weight–based chemotherapy dosing for morbidly obese patients with cancer, subject to appropriate consideration of other comorbid conditions. Data are extremely limited regarding optimal dose selection among the morbidly obese and other special subgroups.
- Full Text
Purpose To provide recommendations for appropriate cytotoxic...
- The Calculation of Actual Or Received Dose Intensity
Two recent reports of the same combination chemotherapy...
- Evaluation of Chemotherapy in Older Patients—An Analysis of The Medical Literature
The high incidence of age-related hearing loss should also...
- Dose Calculation of Anticancer Drugs
PURPOSETo review the current dose-calculation practice and...
- Prognostic Significance of Actual Dose Intensity in Diffuse Large-Cell Lymphoma
While diffuse large-cell lymphoma (DLCL) is considered to be...
- Paclitaxel Pharmacokinetics, Threshold Models, and Dosing Strategies
Get full access to this article. View all available purchase...
- Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy
Results: Dose reductions ≥15% occurred in 36.5% of patients,...
- Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens
Purpose Breast cancer outcomes are worse among black women...
- Full Text
3 Μαΐ 2021 · The Panel continues to recommend that full, weight-based cytotoxic chemotherapy doses be used to treat obese adults with cancer. New to this version of the guideline, the Panel also recommends that full, approved doses of immunotherapy and targeted therapies be offered to obese adults with cancer.
The given average dose intensity was F 185 mg/m2/2, E 26.4 mg/m2/2 and C 336 mg.m2/2 (representing 93%, 132% and 168% of intended doses of standard regimen). Overall response rate for 21 patients was 81%; CI, 66% to 96%), including six complete responses (23%; CI 7 %-39%).
1 Μαΐ 2018 · Dose-Dense AC (DD-AC, Doxorubicin + Cyclophosphamide) + TH (Taxol® + Herceptin®) is a Chemotherapy Regimen for Breast Cancer - early stage. How does Dose-Dense AC + TH work? Doxorubicin, cyclophosphamide, and paclitaxel are designed to kill or slow the growth of cancer cells.
The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m 2; weight of 75 kg; and creatinine clearance of 75 mL/min. One off loading doses and ongoing maintenance doses are not included in protocol cost calculations.
7 Νοε 2016 · We reviewed management issues in the obese patient with cancer, focusing on how obesity influences treatment selection (including chemotherapy dosing), affects chemotherapy toxicity and surgical complications, and might be a treatment effect modifier.
25 Μαΐ 2023 · The following examples show overall survival rates for people with different types of cancer, along with the percentage of those receiving chemotherapy as part of their treatment. The...
